RxDoctor Payments Data
★ My doctorsLook up a doctor →

Lynt Johnson, MD

Transplant Surgery · Washington, DCNPI 1114926565

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $108,785 of the $153,777 with a category attached, or 70.7%. Dilon Technologies, Inc. accounts for 84.1% of it on its own, with 32 other manufacturers making up the rest. 2025 is the largest year on record at $127,763, more than ten times the $4,405 reported in 2019.

$153,777in general payments, 2019–2025

Across 253 payments — averaging $607.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dilon Technologies, Inc.$129K
  • Intuitive Surgical$9K
  • Boston Scientific$4K
  • Asensus Surgical, Inc.$3K
  • Veloxis Pharmaceuticals, Inc.$3K
  • Transmedics, Inc.$2K
  • plus $4K from 27 others

What the payments were for

  • Consulting fees$108,78571%
  • Speaking & faculty fees$2,3001%
  • Travel & lodging$27,11018%
  • Food & beverage$11,5077%
  • Education$4,0673%
  • Gifts$90%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Dilon Technologies, Inc.85$129,340
Intuitive Surgical29$8,820
Boston Scientific21$3,884
Asensus Surgical, Inc.18$3,481
Veloxis Pharmaceuticals, Inc.22$2,975
Transmedics, Inc.2$1,663
Covidien LP5$798
Medtronic5$328
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC12$270
Madrigal Pharmaceuticals2$270
Mallinckrodt Hospital Products Inc.5$224
Shionogi Inc15$213
AstraZeneca4$194
Gilead3$172
Takeda Pharmaceuticals U.S.A., Inc.3$170
Innovation Technologies Inc1$139
Intera Oncology, Inc1$125
Sanofi-aventis U.S. LLC1$114
Aroa Biosurgery Incorporated2$104
BD1$92
Baxter Healthcare2$63
Davol Inc.1$55
Merck2$46
AbbVie2$44
Astellas Pharma US Inc1$30
Johnson & Johnson1$28
Ipsen Biopharmaceuticals, Inc1$26
Teleflex LLC1$23
Intercept Pharmaceuticals, Inc.1$20
Stryker1$19
Novo Nordisk1$19
Melinta Therapeutics, LLC1$16
Potrero Medical, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few transplant surgery providers in District of Columbiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$111,968
Medicare patients
80
Services billed
164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other transplant surgery in Washington

See the full list for District of Columbia →

Where these figures come from

Is this you, or does something look wrong? →